From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers.
.
NQO2-IN-1 (Compound 20b) is the inhibitor for quinone oxidoreductase (NQO) that inhibits NQO2 with an IC50 of 95 nM. NQO2-IN-1 overcomes the resistance of NSCLC cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by induction of ROS and apoptosis .
Nemadipine-A is a specific inhibitor of the EGL-19 L-type Ca 2+ channel . Nemadipine-A, a cell-permeable L-type calcium channel inhibitor, sensitizes TRAIL-resistant cancer cells to this ligand .
Tnfsf10 Rat Pre-designed siRNA Set A contains three designed siRNAs for Tnfsf10 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
TNFSF10 Human Pre-designed siRNA Set A contains three designed siRNAs for TNFSF10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Tnfsf10 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tnfsf10 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
TNFRSF10D Human Pre-designed siRNA Set A contains three designed siRNAs for TNFRSF10D gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
TNFRSF10C Human Pre-designed siRNA Set A contains three designed siRNAs for TNFRSF10C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
TNFRSF10B Human Pre-designed siRNA Set A contains three designed siRNAs for TNFRSF10B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Isofistularin-3 is a direct, DNA-competitive DNMT1 inhibitor, with an IC50 of 13.5 μM. Isofistularin-3, as a DNA demethylating agent, induces cell cycle arrest and sensitization to TRAIL in cancer cells. Isofistularin-3 can be used as an ADC cytotoxin .
MS78 is an acetylation targeting chimera (AceTAC) that acetylates the p53 tumor suppressor protein. MS78 recruits histone acetyltransferase p300/CBP to acetylate the p53Y220C mutant. MS78 upregulates TRAIL apoptotic genes and downregulates DNA damage response pathways. MS78 contains a CBP/p300 binder, a p53Y220C binder and a linker .
Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells .
1,5,15-Trimethylmorindol is an anthraquinone isolated from the leaves of Morinda citrifolia. 1,5,15- trimethylmorindol (25 μg/mL) does not show significant cytotoxic activity on the human T-cell leukemia cell line, Jurkat, by itself but it shows cytotoxicity (IC50 14.5-15.0 μg/mL) when combined with 0.5-1.5 μg/mL of TRAIL in the cell proliferation assay .
Irigenin (Standard) is the analytical standard of Irigenin. This product is intended for research and analytical applications. Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells .
PH11 is a novel focal adhesion kinase (FAK) inhibitor that rapidly induces apoptosis in TRAIL-resistant PANC-1 cells when combined with TRAIL, but has no effect on normal human fibroblasts. The study found that PH11 downregulates c-FLIP through inhibition of FAK and phosphatidylinositol-3-kinase (PI3K)/AKT pathways, thereby restoring the TRAIL apoptotic pathway, suggesting that this combination therapy may provide an attractive therapeutic strategy for the safe and effective treatment of pancreatic cancer. PH11 selectively inhibits c-FLIP expression by modulating upstream signaling pathways and may represent an innovative therapeutic strategy. Although further work is needed to fully elucidate the mechanism of PH11-induced TRAIL sensitization, we believe that our results will provide a new approach to target c-FLIP without the risk of interfering with caspase-8 processing, which could potentially lead to TRAIL resistance. This study also suggests a role for the FAK/AKT signaling pathway in regulating c-FLIP expression in TRAIL-induced apoptosis, and this understanding will provide important clues to control the resistance mechanism to optimize the potential of TRAIL-based pancreatic cancer treatment.
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .
Desacetylxanthanol (Compound 4) is a sesquiterpenoid derived from Xanthium strumarium. Desacetylxanthanol has anti-tumor necrosis factor-associated apoptosis-inducing ligand (TRAIL) activity .
Pinoresinol is a lignol of plant origin serving for defense in a caterpillar. Pinoresinol drastically sensitizes cancer cells against TNF-related apoptosis-inducing ligand (TRAIL) -induced apoptosis .
Bioymifi (DR5 Activator), a potent TRAIL receptor DR5 activator, binds to the extracellular domain (ECD) of DR5 with a Kd of 1.2 μM. Bioymifi can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis .
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer .
Pinoresinol (Standard) is the analytical standard of Pinoresinol. This product is intended for research and analytical applications. Pinoresinol is a lignol of plant origin serving for defense in a caterpillar. Pinoresinol drastically sensitizes cancer cells against TNF-related apoptosis-inducing ligand (TRAIL) -induced apoptosis .
Quercetin 3,4′-dimethyl ether (3,4′-Dimethylquercetin) is a dimethoxyflavone can be isolated from Combretum quadrangulare. Quercetin 3,4′-dimethyl ether overcomes TRAIL resistance by enhancing DR5 expression and has anti-tumor activity .
(E)-3-Dodecenol is a termite trail pheromone that can be isolated from the whole body and thymus extracts of termite workers. (E)-3-Dodecenol induces orientational and recruitment behavior effects, but its induction effect is weaker than (Z)-Dodecenol or natural thymus extracts .
Eftozanermin alfa (ABBV-621) is a second-generation tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) agonist. Eftozanermin alfa induces apoptosis in tumor cells by activation of death receptors 4/5. Eftozanermin alfa can be used for the research of multiple solid and heme malignancies .
LY 303511 hydrochloride is a structural analogue of LY294002. LY303511 does not inhibit PI3K. LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells. LY303511 reversibly blocks K + currents (IC50=64.6±9.1 μM) in MIN6 insulinoma cells.
LBW242, a 3-mer and Smac mimetic, is a potent and orally active proapoptotic IAP inhibitor. LBW242 shows effects on mutant FLT3-expressing cells. LBW242 has activity against multiple myeloma, and potentiates TRAIL- and anticancer agent-mediated cell death of ovarian cancer cells .
LY303511 is a structural analogue of LY294002. LY303511 does not inhibit PI3K. LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells. LY303511 reversibly blocks K + currents (IC50=64.6±9.1 μM) in MIN6 insulinoma cells.
LY 303511 dihydrochloride is a structural analogue of LY294002. LY 303511 dihydrochloride does not inhibit PI3K. LY 303511 dihydrochloride enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells. LY 303511 dihydrochloride reversibly blocks K + currents (IC50=64.6±9.1 μM) in MIN6 insulinoma cells.
2-Methylhexacosane is a saturated hydrocarbon and an insect pheromone. It has been found in the cuticle of M. dasystomus females, but not males, where it contributes to the mating behavior of males, as well as in D. melanogaster females where it modulates aggression of males towards females. 2-methylhexacosane has also been found in yellow jacket (V. vulgaris) trail extracts.
API-1 is a potent selective Akt/PKB inhibitor that reduces the level of phosphorylated Akt (IC50 = 0.8 μM). API-1 binds to the PH domain and inhibits Akt membrane translocation. API-1 induces c-FLIP degradation. API-1 reduces cell proliferation and induces apoptosis. API-1 decreases tumor growth in mouse xenograft model .
3,4-Dicaffeoylquinic acid (3,4-Di-O-caffeoylquinic acid), naturally isolated from Laggera alata, has antioxidative, DNA protective, neuroprotective and hepatoprotective properties. 3,4-Dicaffeoylquinic acid exerts apoptosis-mediated cytotoxicity and α-glucosidase inhibitory effects. 3,4-Dicaffeoylquinic acid possesses a unique mechanism of anti-influenza viral activity, that is, enhancing viral clearance by increasing TRAIL .
BAY 61-3606 hydrochloride is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a Ki of 7.5 nM and an IC50 of 10 nM . BAY 61-3606 hydrochloride reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell. BAY 61-3606 hydrochloride induces a large decrease of Syk phosphorylation in K-rn cell lysates. BAY 61-3606 hydrochloride sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells.
BAY 61-3606 is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a Ki of 7.5 nM and an IC50 of 10 nM . BAY 61-3606 reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell . BAY 61-3606 induces a large decrease of Syk phosphorylation in K-rn cell lysates . Bay 61-3606 sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells .
BAY 61-3606 dihydrochloride is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a Ki of 7.5 nM an IC50 of 10 nM . BAY 61-3606 dihydrochloride reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell . BAY 61-3606 dihydrochloride induces a large decrease of Syk phosphorylation in K-rn cell lysates . Bay 61-3606 dihydrochloride sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells .
3,4-Dicaffeoylquinic acid (Standard) is the analytical standard of 3,4-Dicaffeoylquinic acid. This product is intended for research and analytical applications. 3,4-Dicaffeoylquinic acid (3,4-Di-O-caffeoylquinic acid), naturally isolated from Laggera alata, has antioxidative, DNA protective, neuroprotective and hepatoprotective properties. 3,4-Dicaffeoylquinic acid exerts apoptosis-mediated cytotoxicity and α-glucosidase inhibitory effects. 3,4-Dicaffeoylquinic acid possesses a unique mechanism of anti-influenza viral activity, that is, enhancing viral clearance by increasing TRAIL .
Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers.
.
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .
Mapatumumab (HGS-ETR1) is a fully human IgG2 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Mapatumumab can be used for the research of cancer .
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer .
Eftozanermin alfa (ABBV-621) is a second-generation tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) agonist. Eftozanermin alfa induces apoptosis in tumor cells by activation of death receptors 4/5. Eftozanermin alfa can be used for the research of multiple solid and heme malignancies .
Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells .
Pinoresinol is a lignol of plant origin serving for defense in a caterpillar. Pinoresinol drastically sensitizes cancer cells against TNF-related apoptosis-inducing ligand (TRAIL) -induced apoptosis .
3,4-Dicaffeoylquinic acid (3,4-Di-O-caffeoylquinic acid), naturally isolated from Laggera alata, has antioxidative, DNA protective, neuroprotective and hepatoprotective properties. 3,4-Dicaffeoylquinic acid exerts apoptosis-mediated cytotoxicity and α-glucosidase inhibitory effects. 3,4-Dicaffeoylquinic acid possesses a unique mechanism of anti-influenza viral activity, that is, enhancing viral clearance by increasing TRAIL .
1,5,15-Trimethylmorindol is an anthraquinone isolated from the leaves of Morinda citrifolia. 1,5,15- trimethylmorindol (25 μg/mL) does not show significant cytotoxic activity on the human T-cell leukemia cell line, Jurkat, by itself but it shows cytotoxicity (IC50 14.5-15.0 μg/mL) when combined with 0.5-1.5 μg/mL of TRAIL in the cell proliferation assay .
Irigenin (Standard) is the analytical standard of Irigenin. This product is intended for research and analytical applications. Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells .
Desacetylxanthanol (Compound 4) is a sesquiterpenoid derived from Xanthium strumarium. Desacetylxanthanol has anti-tumor necrosis factor-associated apoptosis-inducing ligand (TRAIL) activity .
Pinoresinol (Standard) is the analytical standard of Pinoresinol. This product is intended for research and analytical applications. Pinoresinol is a lignol of plant origin serving for defense in a caterpillar. Pinoresinol drastically sensitizes cancer cells against TNF-related apoptosis-inducing ligand (TRAIL) -induced apoptosis .
Quercetin 3,4′-dimethyl ether (3,4′-Dimethylquercetin) is a dimethoxyflavone can be isolated from Combretum quadrangulare. Quercetin 3,4′-dimethyl ether overcomes TRAIL resistance by enhancing DR5 expression and has anti-tumor activity .
(E)-3-Dodecenol is a termite trail pheromone that can be isolated from the whole body and thymus extracts of termite workers. (E)-3-Dodecenol induces orientational and recruitment behavior effects, but its induction effect is weaker than (Z)-Dodecenol or natural thymus extracts .
3,4-Dicaffeoylquinic acid (Standard) is the analytical standard of 3,4-Dicaffeoylquinic acid. This product is intended for research and analytical applications. 3,4-Dicaffeoylquinic acid (3,4-Di-O-caffeoylquinic acid), naturally isolated from Laggera alata, has antioxidative, DNA protective, neuroprotective and hepatoprotective properties. 3,4-Dicaffeoylquinic acid exerts apoptosis-mediated cytotoxicity and α-glucosidase inhibitory effects. 3,4-Dicaffeoylquinic acid possesses a unique mechanism of anti-influenza viral activity, that is, enhancing viral clearance by increasing TRAIL .
TRAIL Protein (TNFSF10), a member of the TNF superfamily, is a type II transmembrane protein. TRAIL Protein mainly interacts with TRAIL-R1 and TRAIL-R2, and induces apoptosis in tumor or infected cells. TRAIL Protein also binds with DR4, DR5, and OPG. TRAIL Protein can recruit FADD and further recruit and activates caspase-8 after binding to DR4 or DR5. Besides, TRAIL may also trigger nonapoptotic signaling through activating pro-inflammatory pathways. TRAIL protein is mainly expressed on surface of immune cells, such as cytotoxic T cells and natural killer (NK) cell. TRAIL/TNFSF10 Protein, Rhesus Macaque is a recombinant Rhesus Macaque TRAIL (V114-G281) without any tag, which is expressed in E. coli.
TRAIL/TNFSF10 protein binds to TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, and possibly TNFRSF11B, inducing apoptosis.It can be modulated by decoy receptors TNFRSF10C, TNFRSF10D, and TNFRSF11B, which do not induce apoptosis.TRAIL/TNFSF10 exists as a homotrimer, interacting with its receptor monomers.This complex molecular interaction governs apoptotic signaling pathways.TRAIL/TNFSF10 Protein, Mouse (His) is the recombinant mouse-derived TRAIL/TNFSF10 protein, expressed by E.coli , with N-6*His labeled tag.
TRAIL R1/TNFRSF10A protein is a receptor for TNFSF10/TRAIL, which recruits caspase-8 through FADD to initiate cell apoptosis and form a death-inducing signaling complex (DISC). It activates NF-kappa-B and interacts with TRADD and RIPK1 in the monomeric state. TRAIL R1/TNFRSF10A Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived TRAIL R1/TNFRSF10A protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
TRAIL Protein (TNFSF10), a member of the TNF superfamily, is a type II transmembrane protein. TRAIL Protein mainly interacts with TRAIL-R1 and TRAIL-R2, and induces apoptosis in tumor or infected cells. TRAIL Protein also binds with DR4, DR5, and OPG. TRAIL Protein can recruit FADD and further recruit and activates caspase-8 after binding to DR4 or DR5. Besides, TRAIL may also trigger nonapoptotic signaling through activating pro-inflammatory pathways. TRAIL protein is mainly expressed on surface of immune cells, such as cytotoxic T cells and natural killer (NK) cell. TRAIL/TNFSF10 Protein, Human (HEK293, His-Flag) is a recombinant human TRAIL (G118-G281) with N-terminal His and Flag tag, which is expressed in HEK293.
TRAIL Protein (TNFSF10), a member of the TNF superfamily, is a type II transmembrane protein. TRAIL Protein mainly interacts with TRAIL-R1 and TRAIL-R2, and induces apoptosis in tumor or infected cells. TRAIL Protein also binds with DR4, DR5, and OPG. TRAIL Protein can recruit FADD and further recruit and activates caspase-8 after binding to DR4 or DR5. Besides, TRAIL may also trigger nonapoptotic signaling through activating pro-inflammatory pathways. TRAIL protein is mainly expressed on surface of immune cells, such as cytotoxic T cells and natural killer (NK) cell. TRAIL/TNFSF10 Protein, Human is a recombinant human TRAIL (V114-G281) without any tag, which is expressed in E. coli.
TRAIL R1/TNFRSF10A protein is a receptor for TNFSF10/TRAIL, which recruits caspase-8 through FADD to initiate cell apoptosis and form a death-inducing signaling complex (DISC). It activates NF-kappa-B and interacts with TRADD and RIPK1 in the monomeric state. TRAIL R1/TNFRSF10A Protein, Human (HEK293, His-Avi) is the recombinant human-derived TRAIL R1/TNFRSF10A protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
TRAIL R1/TNFRSF10A protein is a receptor for TNFSF10/TRAIL, which recruits caspase-8 through FADD to initiate cell apoptosis and form a death-inducing signaling complex (DISC). It activates NF-kappa-B and interacts with TRADD and RIPK1 in the monomeric state. TRAIL R1/TNFRSF10A Protein, Human (HEK293, hFc) is the recombinant human-derived TRAIL R1/TNFRSF10A protein, expressed by HEK293 , with C-hFc labeled tag.
TRAIL R2/TNFRSF10B Protein serves as a receptor for the cytotoxic ligand TNFSF10/TRAIL. Upon ligand binding, the adapter molecule FADD recruits caspase-8 to the activated receptor, forming the death-inducing signaling complex (DISC). This activation leads to a cascade of caspases, mediating apoptosis. TRAIL R2/TNFRSF10B lacks conserved residue(s) crucial for feature annotation propagation. TRAIL R2/TNFRSF10B Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-His labeled tag.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and activates apoptosis through FADD-mediated recruitment of caspase-8 to form death-inducing signaling complex (DISC).It initiates caspase cascade-mediated apoptosis and promotes NF-kappa-B activation, which is critical for ER stress-induced apoptosis.TRAIL R2/TNFRSF10B Protein, Mouse (HEK293, His) TRAIL R2/TNFRSF10B Protein, Mouse (HEK293, His) is the recombinant mouse-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-His labeled tag.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and recruits caspase-8 through FADD to initiate cell apoptosis. It forms the death-inducing signaling complex (DISC), activates caspases and mediates apoptosis. TRAIL R2/TNFRSF10B Protein, Human (HEK293, His-Avi) is the recombinant human-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and recruits caspase-8 through FADD to initiate cell apoptosis. It forms the death-inducing signaling complex (DISC), activates caspases and mediates apoptosis. TRAIL R2/TNFRSF10B Protein, Human (HEK293, hFc) is the recombinant human-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-hFc labeled tag.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and recruits caspase-8 through FADD to initiate cell apoptosis. It forms the death-inducing signaling complex (DISC), activates caspases and mediates apoptosis. TRAIL R2/TNFRSF10B Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and recruits caspase-8 through FADD to initiate cell apoptosis. It forms the death-inducing signaling complex (DISC), activates caspases and mediates apoptosis. TRAIL R2/TNFRSF10B Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-His labeled tag.
TRAIL R1/TNFRSF10A protein is a receptor for TNFSF10/TRAIL, which recruits caspase-8 through FADD to initiate cell apoptosis and form a death-inducing signaling complex (DISC). It activates NF-kappa-B and interacts with TRADD and RIPK1 in the monomeric state. TRAIL R1/TNFRSF10A Protein, Human (216a.a, HEK293, His) is the recombinant human-derived TRAIL R1/TNFRSF10A protein, expressed by HEK293 , with C-6*His labeled tag.
TRAIL/TNFSF10 protein is a cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4, and possibly TNFRSF11B/OPG. It induces apoptosis, a process that can be mediated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4, and TNFRSF11B/OPG, which lack the ability to induce apoptosis. TRAIL/TNFSF10 Protein, Human (N-His) is the recombinant human-derived TRAIL/TNFSF10 protein, expressed by E. coli , with N-6*His labeled tag.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and recruits caspase-8 through FADD to initiate cell apoptosis. It forms the death-inducing signaling complex (DISC), activates caspases and mediates apoptosis. TRAIL R2/TNFRSF10B Protein, Human (127a.a, HEK293, His) is the recombinant human-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-6*His labeled tag.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and recruits caspase-8 through FADD to initiate cell apoptosis. It forms the death-inducing signaling complex (DISC), activates caspases and mediates apoptosis. TRAIL R2/TNFRSF10B Protein, Human is the recombinant human-derived TRAIL R2/TNFRSF10B protein, expressed by E. coli , with tag free.
TRAILR4/TNFRSF10D protein is a receptor for TRAIL and lacks the ability to induce apoptosis due to the truncated death domain. Paradoxically, not only does it fail to induce apoptosis, but it also prevents TRAIL-mediated apoptosis. TRAILR4/TNFRSF10D Protein, Human (HEK293, Fc) is the recombinant human-derived TRAILR4/TNFRSF10D protein, expressed by HEK293 , with C-hFc labeled tag.
TRAILR4/TNFRSF10D protein is a receptor for TRAIL and lacks the ability to induce apoptosis due to the truncated death domain. Paradoxically, not only does it fail to induce apoptosis, but it also prevents TRAIL-mediated apoptosis. TRAILR4/TNFRSF10D Protein, Human (HEK293, His) is the recombinant human-derived TRAILR4/TNFRSF10D protein, expressed by HEK293 , with C-His labeled tag.
TRAILR4/TNFRSF10D Protein , a receptor for TRAIL. Paradoxically, it not only fails to induce apoptosis but also protects against TRAIL-mediated apoptosis. Conflicting reports exist about its role in activating the NF-kappa-B pathway. The dual nature of TRAILR4 in interacting with TRAIL, both as a receptor and a protective factor, highlights the complexity of its regulatory functions in cellular responses to TRAIL signaling. TRAILR4/TNFRSF10D Protein, Rhesus Macaque (HEK293, Fc) is the recombinant Rhesus Macaque-derived TRAILR4/TNFRSF10D protein, expressed by HEK293 , with C-hFc labeled tag.
TRAILR4/TNFRSF10D Protein , a receptor for TRAIL. Paradoxically, it not only fails to induce apoptosis but also protects against TRAIL-mediated apoptosis. Conflicting reports exist about its role in activating the NF-kappa-B pathway. The dual nature of TRAILR4 in interacting with TRAIL, both as a receptor and a protective factor, highlights the complexity of its regulatory functions in cellular responses to TRAIL signaling. TRAILR4/TNFRSF10D Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived TRAILR4/TNFRSF10D protein, expressed by HEK293 , with C-His labeled tag.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and activates apoptosis through FADD-mediated recruitment of caspase-8 to form death-inducing signaling complex (DISC).It initiates caspase cascade-mediated apoptosis and promotes NF-kappa-B activation, which is critical for ER stress-induced apoptosis.TRAIL R2/TNFRSF10B Protein, Mouse (HEK293, hFc) is the recombinant mouse-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-hFc labeled tag.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and activates apoptosis through FADD-mediated recruitment of caspase-8 to form death-inducing signaling complex (DISC).It initiates caspase cascade-mediated apoptosis and promotes NF-kappa-B activation, which is critical for ER stress-induced apoptosis.TRAIL R2/TNFRSF10B Protein, Mouse (HEK293, His-Fc) is the recombinant mouse-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-hFc, C-His labeled tag.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and activates apoptosis through FADD-mediated recruitment of caspase-8 to form death-inducing signaling complex (DISC).It initiates caspase cascade-mediated apoptosis and promotes NF-kappa-B activation, which is critical for ER stress-induced apoptosis.TRAIL R2/TNFRSF10B Protein, Mouse (HEK293, Avi-His) is the recombinant mouse-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag.
The TNFRSF10C protein is a receptor for TRAIL and lacks a cytoplasmic death domain, making it unable to induce apoptosis. Instead, it protects cells by competing for ligand binding with TRAIL-R1 and R2, acting as a decoy receptor and mitigating TRAIL-mediated apoptosis. TNFRSF10C Protein, Human (HEK293, His) is the recombinant human-derived TNFRSF10C protein, expressed by HEK293 , with C-6*His labeled tag.
TRAIL/TNFSF10 protein is a cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4, and possibly TNFRSF11B/OPG. It induces apoptosis, a process that can be mediated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4, and TNFRSF11B/OPG, which lack the ability to induce apoptosis. Animal-Free TRAIL/TNFSF10 Protein, Human (His) is the recombinant human-derived animal-FreeTRAIL/TNFSF10 protein, expressed by E. coli , with C-His labeled tag. This product is for cell culture use only.
TRAIL/TNFSF10 protein binds to TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, and possibly TNFRSF11B, inducing apoptosis.It can be modulated by decoy receptors TNFRSF10C, TNFRSF10D, and TNFRSF11B, which do not induce apoptosis.TRAIL/TNFSF10 exists as a homotrimer, interacting with its receptor monomers.This complex molecular interaction governs apoptotic signaling pathways.Animal-Free TRAIL/TNFSF10 Protein, Mouse (His) is the recombinant mouse-derived animal-FreeTRAIL/TNFSF10 protein, expressed by E.coli , with C-His labeled tag.This product is for cell culture use only.
The TNFRSF10C protein is a receptor for TRAIL and lacks a cytoplasmic death domain, making it unable to induce apoptosis. Instead, it protects cells by competing for ligand binding with TRAIL-R1 and R2, acting as a decoy receptor and mitigating TRAIL-mediated apoptosis. TNFRSF10C Protein, Human (210a.a, HEK293, His) is the recombinant human-derived TNFRSF10C protein, expressed by HEK293 , with C-His labeled tag.
Fas like protein; Apoptosis inducing protein TRICK2A/2B; Apoptosis inducing receptor TRAIL R2; CD 262; CD262; CD262 antigen; Cytotoxic TRAIL receptor 2; Death domain containing receptor for TRAIL/Apo 2L; Death domain containing receptor for TRAIL/Apo2L; D
WB, ICC/IF
Human, Mouse
TNFRSF10B Antibody (YA660) is a non-conjugated and Mouse origined monoclonal antibody about 48 kDa, targeting to TNFRSF10B (7F4). It can be used for WB,ICC/IF assays with tag free, in the background of Human, Mouse.
TNFRSF10D; DCR2; TRAILR4; TRUNDD; Tumor necrosis factor receptor superfamily member 10D; Decoy receptor 2; DcR2; TNF-related apoptosis-inducing ligand receptor 4; TRAIL receptor 4; TRAIL-R4; TRAIL receptor with a truncated death domain; CD
WB, IHC-P, ICC/IF
Human
DcR2 Antibody (YA2588) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2588), targeting DcR2, with a predicted molecular weight of 42 kDa (observed band size: 36 kDa). DcR2 Antibody (YA2588) can be used for WB, IHC-P, ICC/IF experiment in human background.
Tnfsf10 Rat Pre-designed siRNA Set A contains three designed siRNAs for Tnfsf10 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
TNFSF10 Human Pre-designed siRNA Set A contains three designed siRNAs for TNFSF10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Tnfsf10 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tnfsf10 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
TNFRSF10D Human Pre-designed siRNA Set A contains three designed siRNAs for TNFRSF10D gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
TNFRSF10C Human Pre-designed siRNA Set A contains three designed siRNAs for TNFRSF10C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
TNFRSF10B Human Pre-designed siRNA Set A contains three designed siRNAs for TNFRSF10B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Inquiry Online
Your information is safe with us. * Required Fields.
